Drugs / giritinib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06972641 | Jun 2025 → Mar 2030 expected | acute myeloid leukemia, myelodysplastic syndrome | Ruijin Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | giritinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06972641 ↗ |
| Route | Oral | “Sorafenib 0.2g 2/day or giritinib 40mg 2/day orally for 2 years” NCT06972641 ↗ |